Methotrexate Inhibits the Binding of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Receptor Binding Domain to the Host-Cell Angiotensin-Converting Enzyme-2 (ACE-2) Receptor-Reference-Cited by-同舟云学术

Methotrexate Inhibits the Binding of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Receptor Binding Domain to the Host-Cell Angiotensin-Converting Enzyme-2 (ACE-2) Receptor

Published:2024-01-16 Issue: Volume: Page:
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Kim Soo-Kyung¹,Suebka Sartanee²,Gin Adley²³,Nguyen Phuong-Diem³,Tang Yisha³,Su Judith²^ORCID,Goddard William A.¹^ORCID

Affiliation:

1. Materials and Process Simulation Center, California Institute of Technology, Pasadena, California 91125, United States

2. Wyant College of Optical Sciences, The University of Arizona, Tucson, Arizona 85721, United States

3. Department of Biomedical Engineering, The University of Arizona, Tucson, Arizona 85721, United States

Funder

National Heart, Lung, and Blood Institute

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.3c00197

Reference50 articles.

1. Advances in Experimental Medicine and Biology;Kolahchi Z.,2021

2. U.K. variant puts spotlight on immunocompromised patients’ role in the COVID-19 pandemic | Science | AAAS. https://www.science.org/content/article/uk-variant-puts-spotlight-immunocompromised-patients-role-covid-19-pandemic (accessed May 2023).

3. Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants (accessed May 2023).

4. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

5. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay